Related Experiment Video
Updated: Oct 9, 2026

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Bone markers and bone mineral density during growth hormone treatment in children with growth hormone deficiency
C T Cowell1, H J Woodhead, J Brody
1Robert Vines Growth Research Centre, Ray Williams Institute of Endocrinology Diabetes and Metabolism, The Children's Hospital at Westmead, Parramatta, NSW, Australia. chrisc@nch.edu.au
Insights
Growth hormone (GH) impacts bone formation and resorption, but its long-term effects on bone mineral density (BMD) in children with GH deficiency (GHD) remain unclear. Further research is needed to understand optimal treatment and long-term bone health outcomes.
Area of Science:
- Pediatric Endocrinology
- Bone Biology
- Growth Hormone Therapy
Background:
- Growth hormone (GH) influences muscle mass, growth, and bone formation, affecting bone turnover markers early in therapy.
- Interpreting the impact of GH deficiency (GHD) and its treatment on bone mineral density (BMD) in children is challenging due to height and weight dependencies.
- Conflicting results exist regarding volumetric BMD changes in children undergoing GH therapy.
Purpose of the Study:
- To review the current understanding of GH's effects on bone in children.
- To highlight the difficulties in assessing long-term bone health outcomes in GHD patients.
- To identify areas for future research in pediatric GH therapy and bone health.
Main Methods:
- Review of existing literature on GH, GHD, and bone health in pediatric populations.
- Discussion of challenges in measuring BMD in growing children.
- Identification of limitations in current studies, such as small sample sizes.
Main Results:
- GH therapy increases bone formation and resorption markers, correlating with short-term growth but not necessarily long-term response.
- Assessing BMD in GHD children is complicated by growth-related changes, with volumetric BMD results being inconsistent.
- Limited data suggests that normalizing bone mass in GHD individuals, even with prolonged GH treatment, may be difficult.
Conclusions:
- Current data is insufficient to fully understand the long-term effects of GH therapy on bone health in GHD children.
- Future research should employ direct bone density measurements (e.g., quantitative CT) and consider structural/geometric bone properties.
- Further studies are needed to clarify the role of GHD severity, GH dosage, IGF-I levels, timing of other therapies, and fracture risk.
Abstract:
Growth hormone (GH) has a positive impact on muscle mass, growth and bone formation. It is known to interact with the bone-forming unit, with well-documented increases in markers of bone formation and bone resorption within weeks of the start of GH therapy. These changes relate significantly to short-term growth rate, but it is not evident that they predict long-term response to GH therapy. The consequences of GH deficiency (GHD) and GH replacement therapy on bone mineral density (BMD) have been difficult to interpret in children because of the dependency of areal BMD on height and weight. Some studies have tried to overcome this problem by calculating volumetric BMD, but results are conflicting. The attainment of a normal peak bone mass in an individual is considered important for the future prevention of osteoporosis. From the limited data available, it appears difficult to normalize bone mass totally in GH-deficient individuals, despite GH treatment for long periods. Studies to date examining the interaction between GH and bone have included only small numbers of individuals, making it difficult to interpret the study findings. It is hoped that these issues can be clarified in future research by the direct measurement of bone density (using quantitative computer tomography). Mineralization is only one facet of bone strength, however; other important components (e.g. bone structure and geometry) should be addressed in future paediatric studies. Future studies could also address the importance of the degree of GHD in childhood; how GH dose and insulin-like growth factor-I levels achieved during therapy relate to the final outcome; whether or not the continuation of GH therapy after the attainment of final height may further enhance bone mass; whether the timing and dose of other treatments (e.g. sex hormone replacement therapy) are critical to the outcome; and whether GHD in childhood is associated with an increased risk of fracture.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Growth of Cartilage and Bone Tissue
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Bone Remodeling